tirzepatide loss of exclusivity The peptide regulatory landscape in 2026 is in active flux. After the FDA placed 19 popular peptides in Category 2 in late 2023, HHS Secretary RFK Jr. announced in February 2026 that Tirzepatide for Medical Weight Loss
Description
Conclusion Our results suggest that, in a real-world setting, once-weekly injectable GLP-1 RAs are associated with better persistence and adherence than daily regimens over 1 year
Short term, they are probably safe, but their long-term use is entirely unclear
UHC also gives Wegovy a 5-month initial approval vs 6 months for Zepbound
doi: 10.1111/j.1463-1326.2010.01204.x
This might mean increasing your medication dose more gradually and combining medication with sustainable nutrition and habit changes
